TUM – Technical University of Munich Menu
m4 Award: The five winner teams
m4 Award: The five winner teams
Image: BioM / Andreas Grasser
  • Entrepreneurship
  • Reading time: 5 MIN

Four TUM research teams receive m4 Awards

From fundamental research to new medications

Four research teams from the Technical University of Munich (TUM) have received m4 Awards this year. The award will bring them two-year grants from the State of Bavaria to continue their fundamental biomedical research and found new companies. Two of the teams honored work on new therapies to fight cancer, while the other two teams are investigating medications against antibiotic-resistant bacteria.

The m4 Award supports research teams planning to found companies that will use their findings to develop innovative products, technologies and services for the medicine of the future. The Bavarian Ministry of Economic Affairs, Regional Development and Energy has supported the competition, launched by BioM, the network organization of the biotechnology sector in Munich and Bavaria, since 2011. Each of the winning teams will receive funding of up to 500,000 euros and will benefit from expert support when founding their companies. This year more than 30 research teams from throughout Bavaria entered the contest for the m4 Award. Four of the five winners are from TUM and will be supported by TUM Start-up Advising team. The winning teams are all led or supported by experienced scientists.

FUSIX Biotech: Viruses against cancer

In their project FUSIX Biotech, Adjunct Teaching Professor Jennifer Altomonte and Teresa Krabbe are researching the treatment of tumors using oncolytic viruses which selectively infect the tumor tissue, causing the cancer cells to die. Past attempts have always encountered challenges: Intravenous application is inefficient in delivering sufficient quantities of virus to the tumor, while the tissue of some tumors is so dense that treatments cannot penetrate them. Working at the TUM's university hospital Klinikum rechts der Isar, the scientists have now engineered a hybrid of two recombinant viruses to develop a superior oncolytic virus which overcomes the known obstacles and has been shown to be effective against primary liver cancer. The new virus is not pathogenic in humans, and humans do not have any pre-existing immunity against it. The award winners now plan to complete their pre-clinical data package and to scale it for clinical-grade production. They hope to reach this milestone within the next two years and to found a company with a marketable product.

LOGIBODY: Developing a nanoswitch for antibodies

Antibody-based immunotherapies promise great potential when it comes to treating tumor diseases. They attach themselves to special structures on the surface of the tumor and can for example attract the body's own immune cells to fight the tumor. Treatment can sometimes lead to an overstimulation of the immune system, resulting in severe side effects. One reason for this is that the target structures are not only present in the tumor, but also in healthy tissue. Now, the LOGIBODY team at the TUM Professorship for Biomolecular Nanotechnology and its mentor Prof. Hendrik Dietz, have developed an "on/off switch" for antibody immunotherapies. The nanoswitch recognizes tumor cells specifically and thus can ensure that immune cells are recruited to the tumor cells. This results in reduced activity in healthy tissue and thus to fewer side-effects. The molecular switch is made up of DNA which here no longer serves as a carrier of genetic information, but rather as a reliable building material for molecular machines on a nanometer scale. LOGIBODY exemplifies the innovation potential of molecular robotics.

FRABIOTICS: Molecular fragments with dual mode of action against multiresistant bacterial pathogens

Dr. Hannelore Meyer, research group leader at the TUM Institute for Medical Microbiology, Immunology and Hygiene, and her FRABIOTICS team in collaboration with the Helmholtz Zentrum München have identified a fragment (very small ‚small molecule'), which blocks bacterial resistance to the most widely used antibiotics. The infections caused by these bacteria include for example certain life-threatening forms of pneumonia and blood poisoning. These fragments have a dual mode of action. Firstly, they shut down the resistance against these antibiotics and thereby protect their efficacy. In addition, they have an antibiotic effect themselves, i.e. they can also fight bacteria without the additional administration of antibiotics. Thanks to this dual mode of action resistance development in the pathogenic bacteria against this treatment is expected to be delayed. The researchers plan to use the m4 Award funding to find the mechanism behind the antibiotic effect of the molecules and optimize it for medicinal application.

aBACTER: Development of a resistance-free antibiotic therapy for the treatment of fatal infectious diseases

In the aBACTER project, Prof. Stephan Sieber, who holds the Chair of Organic Chemistry II at TUM, Dr. Franziska Mandl, Dr. Christian Fetzer, and Dr. Mathias Hackl are developing a novel anti-infective against multiresistant bacteria which often cannot even be treated with reserve antibiotics such as vancomycin; according to estimates, such germs are responsible for several thousands of deaths in Germany each year. The new antibiotic intervenes in several cell processes in the bacteria which are not attacked by currently approved antibiotics. This means that multiresistant bacteria have no defense against this new antibiotic and that it is significantly less probable that bacteria will become resistant against it: They would have to develop simultaneous resistances to the various cell processes addressed. In the long term, the new antibiotic could be used to fight a large number of diseases. The researchers plan to use it first against endocarditis, a dangerous infection of the endocardium for which there are already only a limited number of therapeutic options. The researchers plan to use the funding from m4-Award for decisive preclinical tests in order to make a large step towards entering the first clinical phase.

More information:

Every year more than 70 technology companies are established at TUM. TUM and UnternehmerTUM support new companies with programs tailored to the phases of the start-up process – from writing the business model to management training, and from market entry to a possible IPO. Up to 30 teams can use offices in the TUM Incubator to prepare the launch of their companies. TUM accompanies the most promising candidates on a two-week trip to Silicon Valley. With its own UVC venture capital fund, UnternehmerTUM invests in young technology companies that demonstrate high potential, offering them access to MakerSpace, a 1,500 square meter high-tech workshop for building prototypes, and the Bio.Kitchen biotech laboratory. According to the respected "Start-up Radar" survey, this support is unparalleled at Germany's major universities.

Corporate Communications Center

Technical University of Munich Dr. Paul Piwnicki
paul.piwnicki(at)tum.de
Tel: +49 89 289 10808

Contacts to this article:

FUSIX Biotech: PD Dr. Jennifer Altomonte, Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Tel: +49 89 4140 2261, jennifer.altomonte(at)tum.de

LOGIBODY: Dr. Benjamin Kick, Dr. Klaus Wagenbauer, Dr. Jonas Funke, Professorship for Biomolecular Nanotechnology,  benjamin.kick(at)tum.de

FRABIOTICS: Dr. Hannelore Meyer, TUM Institute for Medical Microbiology, Immunology and Hygiene, Tel: +49 89 4140 6254, hannelore.meyer(at)tum.de

aBACTER: Prof. Stephan Sieber, Chair of Organic Chemistry II, Tel: +49 89 289 13302,  stephan.sieber(at)tum.de

Article at tum.de

A researcher is connected to a computer via a brain-computer-interface.Gehirn-Rechner-Schnittstelle mit einem Rechner verbunden.

From health care to space robotics

Each year, US space agency NASA asks startups with ideas that could improve space exploration to apply for their iTech initiative. Among the ten finalists in the current competition (October 7 and 8) is MyelinS. This...

Four "Innovators under 35" 2019 studied at the TUM and founded their start-ups with the support of TUM and UnternehmerTUM.

Honors for young start-up founders

Rocket drives using liquid oxygen, longer-lasting batteries for electric vehicles, custom-tailored implants from the 3D printer and automated management of tissue samples: Four alumni of the Technical University of Munich...

The winners of the Munich Business Plan Competition.

TUM spin-offs take all three podium positions

In the Munich Business Plan Competition, the top three spots were claimed by start-ups incubated at the Technical University of Munich (TUM). The winner, presize.ai, offers software that enables online shoppers to take...

The award winner Prof. Hans-Jürgen Wester (center) with the winners of a live pitch, TUM Vice President Prof. Thomas Hofmann and UnternehmerTUM Managing Director Helmut Schönenberger.

TUM Presidential Entrepreneurship Award goes to Scintomics

This year the Technical University of Munich (TUM) has presented its Presidential Entrepreneurship Award to Scintomics GmbH. The company develops, produces and markets innovative radio-pharmaceutical and nuclear medicine...

Thiersch Turm und Frauenkirche im Abendlicht (Bild: Heddergott / TUM)

Munich founders increasingly successful

Nine of the "Top 50 Start-ups 2018" come from the Technical University of Munich (TUM), according to an evaluation by the German magazine for start-up founders Für-Gründer.de. Munich, with ten start-ups, is the...

Martin Klenk, Bastian Nominacher und Alexander Rinke

The first “unicorn” from TUM

Celonis has taken its place among the “unicorns”, as the world's most successful start-ups are known: The spin-off from the Technical University of Munich (TUM) has been valued by investors at 1 billion dollars. Celonis...